Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
The highly-anticipated fifth edition is here! Get the must-have resource for achieving compliance with medical device regulations.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 09 August 2012 | By Alexander Gaffney, RAC
The US Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) has released an updated version of the list of guidance documents it plans to release during 2012, revealing all previously announced guidance remains on track for a 2012 release.
The list, "Guidance Agenda - New & Revised Draft Guidances CDER is Planning to Publish During Calendar Year 2012," contains 61 guidance documents divided into 16 categories, including advertising, biopharmaceutics, biosimilarity, clinical, combination products, current good manufacturing practices, electronic submissions, labeling and procedures.
Compared to a list of the same name released by CDER in March 2012, it contains no changes. While many of the guidance documents have since been released by the agency, some, including a hotly anticipated guidance on demonstrating biosimilarity using pharmacology data and a host of electronic submission guidances, remain unreleased.
Tags: Guidance Agenda, Latest News, guidance, regulatory